Ventyx Biosciences, Inc.
Ventyx Biosciences, Inc. Q4 FY2022 earnings call
March 23, 2023 · fiscal period ended 2022-12
EPS · actual vs est
Revenue · actual vs est
Summary
Generated 2023-03-23
Management highlights
Raju Mohan reiterated 2022 was a year of progress, noting positive Phase I results for VTX-958, initiation of three Phase 2 programs with VTX958, positive Phase 1 data for VTX2735, initiation of a Phase 2 proof of mechanism trial for VTX2735 in CAPS, and progress on VTX3232. Bill Sandborn provided updates on VTX958 Phase 2 trials (SERENITY in psoriasis, HARMONY in Crohn’s disease, TRANQUILITY in psoriatic arthritis), enrollment progress for VTX002 in ulcerative colitis, initiation of VTX2735 Phase 2 trial, and plans for VTX3232 Phase 1 trial.
Segment performance
No detailed product segment financial performance provided in the transcript.
Guidance
Top line Phase 2 data for VTX002 in ulcerative colitis expected in second half 2023. Top line data from SERENITY trial of VTX958 in plaque psoriasis expected in Q4 2023. Phase 2 data readouts for VTX958 in psoriatic arthritis and Crohn’s disease expected in 2024. VTX002 enrollment on track to complete by mid-2023.
Risks
Uncertainties in clinical trial outcomes, including safety and efficacy of pipeline candidates. Risks related to regulatory approvals and market acceptance. Impact of competitive landscape on trial results and market position.
Q&A highlights
Q: Michael Yee asked about second-generation TYK2 data and implications for VTX958's psoriasis and Crohn's disease data.
A: Bill Sandborn discussed next-gen TYK2 data and VTX958's target coverage.
Q: Yasmeen Rahimi asked about plateauing effect in psoriasis and enrollment in SERENITY trial.
A: Raju Mohan and Bill Sandborn addressed plateauing and enrollment progress.
Q: Pete asked about VTX2735 Phase 2 trial in CAPS.
A: Bill Sandborn explained proof of concept for VTX2735 in CAPS.
Q: Jeff asked about VTX002 program and Etrasimod data.
A: Bill Sandborn discussed VTX002's positioning and analogy to multiple sclerosis data.
Q: Chris Shibutani asked about VTX958's tolerability and program design.
A: Raju Mohan and Bill Sandborn talked about program design and CPK tolerability.
Q: Romney asked about NLRP3 inhibitors' IL-1β reduction and extended release of VTX958.
A: Raju Mohan and Bill Sandborn discussed IL-1β reduction and extended release plans.
Q: Emily Bodnar asked about VTX958's safety and oral psoriasis market.
A: Raju Mohan and Bill Sandborn addressed safety concerns and market perspectives.
Q: Pat asked about IL-4 receptor alpha program.
A: Raju Mohan talked about IL-4 receptor alpha program's proof of mechanism.
Key numbers
Reported versus consensus
Earnings calendar feed
| Metric | Reported | Consensus | Delta | Prior year |
|---|---|---|---|---|
| EPS | $-0.62 | $-0.59 | -5.1% | — |
| Revenue | — | — | — | — |
Transcript
March 23, 2023Full transcript unavailable for redistribution
The structured summary above covers the available call sections. Full transcript text is not included on this page.
Continue exploring
Prior quarters
This page presents the stored structured earnings-call summary and deterministic earnings calendar values. How this is generated. For informational purposes only; not investment advice.